Information Provided By: 
Fly News Breaks for April 22, 2016
RIGL
Apr 22, 2016 | 06:02 EDT
JPMorgan analyst Anupam Rama upgraded Rigel Pharmaceuticals to Overweight ahead of the top-line phase 3 fostamatinib data in idiopathic thrombocytopenic purpura. The analyst sees high probabilities of success in the two phase 3 trials. The data is expected in mid-2016. Rigel shares have 90%-150% upside on positive data versus 55% downside from current levels in the worst case scenario, Rama tells investors in a research note. The analyst keeps a $5 price target for the shares. The stock closed yesterday up 2c to $2.49.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
